| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England journal of medicine 364 (19), 1817-1825, 2011 | 8371 | 2011 |
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer A Lievre, JB Bachet, D Le Corre, V Boige, B Landi, JF Emile, JF Côté, ... Cancer research 66 (8), 3992-3995, 2006 | 2843 | 2006 |
| FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... New England Journal of Medicine 379 (25), 2395-2406, 2018 | 2686 | 2018 |
| KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ... Journal of clinical oncology 26 (3), 374-379, 2008 | 1968 | 2008 |
| Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, ... Journal of clinical oncology 27 (35), 5924-5930, 2009 | 872 | 2009 |
| Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised … T Conroy, JF Bosset, PL Etienne, E Rio, É François, N Mesgouez-Nebout, ... The Lancet Oncology 22 (5), 702-715, 2021 | 815 | 2021 |
| Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up T Seufferlein, JB Bachet, E Van Cutsem, P Rougier Annals of oncology 23, vii33-vii40, 2012 | 498 | 2012 |
| Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features F Puleo, R Nicolle, Y Blum, J Cros, L Marisa, P Demetter, E Quertinmont, ... Gastroenterology 155 (6), 1999-2013. e3, 2018 | 470 | 2018 |
| Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter … C Tournigand, T André, F Bonnetain, B Chibaudel, G Lledo, T Hickish, ... Journal of clinical oncology 30 (27), 3353-3360, 2012 | 430 | 2012 |
| Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma R Maréchal, JB Bachet, JR Mackey, C Dalban, P Demetter, K Graham, ... Gastroenterology 143 (3), 664-674. e6, 2012 | 284 | 2012 |
| Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker D Pietrasz, N Pécuchet, F Garlan, A Didelot, O Dubreuil, S Doat, ... Clinical Cancer Research 23 (1), 116-123, 2017 | 273 | 2017 |
| Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial FC Bidard, F Huguet, C Louvet, L Mineur, O Bouché, B Chibaudel, P Artru, ... Annals of oncology 24 (8), 2057-2061, 2013 | 226 | 2013 |
| Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness J Leca, S Martinez, S Lac, J Nigri, V Secq, M Rubis, C Bressy, A Sergé, ... The Journal of clinical investigation 126 (11), 4140-4156, 2016 | 217 | 2016 |
| Current standards and new innovative approaches for treatment of pancreatic cancer T Conroy, JB Bachet, A Ayav, F Huguet, A Lambert, C Caramella, ... European Journal of Cancer 57, 10-22, 2016 | 216 | 2016 |
| Unicancer GI PRODIGE 24/CCTG PA. 6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected … T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... Journal of Clinical Oncology 36 (18_suppl), LBA4001-LBA4001, 2018 | 193 | 2018 |
| Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort A Portal, S Pernot, D Tougeron, C Arbaud, AT Bidault, ... British journal of cancer 113 (7), 989-995, 2015 | 189 | 2015 |
| FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort L Marthey, A Sa-Cunha, JF Blanc, M Gauthier, A Cueff, E Francois, ... Annals of surgical oncology 22, 295-301, 2015 | 186 | 2015 |
| Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC) C Neuzillet, S Gaujoux, N Williet, JB Bachet, L Bauguion, LC Durand, ... Digestive and Liver Disease 50 (12), 1257-1271, 2018 | 185 | 2018 |
| Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ... JAMA oncology 8 (11), 1571-1578, 2022 | 176 | 2022 |
| Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label … T André, D Vernerey, L Mineur, J Bennouna, J Desrame, R Faroux, ... Journal of clinical oncology 36 (15), 1469-1477, 2018 | 167 | 2018 |